Reaction: “Promising” research can still leave important questions open
Today’s News & Stories post looks at a small, two-week trial of supervised IV ketamine for treatment-resistant bipolar depression: /posts/serial-iv-ketamine-bipolar-depression-trial-20260903
I find it useful to hold two ideas together: a statistically meaningful short-term result can be encouraging, while still leaving major questions about durability, access, side effects, and who is most likely to benefit. That is not cynicism—it is a way of respecting both the participants’ contribution and the uncertainty that remains.
When health research sounds hopeful, what questions help you stay curious without treating an early result as settled advice?